Tim Horn

Tim Horn

Auto-generated profile, based on publicly available information

Tim Horn

NASTAD , Washington, District of Columbia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
KMKathleen A McManus
Kathleen A McManus
ERErin Q Rogers
Erin Q Rogers
ASAmber Steen
Amber Steen
AKAmy Killelea
Amy Killelea
THTim Horn
Tim Horn
JKJessica Keim-Malpass
Jessica Keim-Malpass
Background: AIDS Drug Assistance Programs (ADAPs), a key part of the federally funded Ryan White HIV/AIDS Program, provide antiretroviral therapy (ART) to low-income and uninsured or underinsured people with HIV. As long as they meet federal regulations, jurisdictions maintain flexibility in implementing ADAPs, allowing for a range of operational and programmatic options, including eligibility criteria, formulary design for ART (and non-ART) drugs, and the nature and character of insurance support. These programmatic and policy decisions ultimately impact ADAP client outcomes, including engagement in care, differences in the populations benefiting from ADAP, and viral suppression rates. Despite ADAPs achieving an 85% national average viral suppression rate, this falls short of the 90% goal needed to end the HIV epidemic, and no formal evaluation has examined how specific operational or policy factors drive success across states. Objective: This qualitative study aims to examine how operational, organizational, and contextual factors shape the ability of ADAPs to improve viral suppression rates among people with HIV enrolled in ADAPs, specifically by identifying the mechanisms that facilitate high performance and viral suppression for all people with HIV. Results will inform how viral suppression outcomes could be improved through policy, program, operational, and organizational changes in ADAP design and implementation. Methods: Using a qualitative descriptive approach guided by the Consolidated Framework for Implementation Research, we conducted semistructured interviews with state-level ADAP leaders, operational and programmatic decision-makers, and staff. Interview questions covered 5 domains: leadership and staffing; operations, integration, and collaboration; formulary design and treatment; eligibility and enrollment; and innovation and implementation. Qualitative data from the interviews will be analyzed using deductive and inductive approaches along with situational mapping. Results: This study was funded in April 2023. In total, 33 individuals from 16 states have participated in this qualitative study, resulting in a participation rate of 31.4% (16/51). States from all 4 US census regions were represented. Interviews were conducted between February 12, 2025, and March 20, 2025. As of March 2026, data analysis is underway. Conclusions: We anticipate that the study will highlight features, organizational practices, and operational norms that contribute to the successes of ADAPs with high rates of viral suppression. Successful completion of this analysis will provide evidence to inform state and federal regulations, program development, resource allocation, and prioritization to advance the goal of helping people achieve viral suppression and interrupt HIV transmission, which is a vital public health objective. Using other data alongside our qualitative findings, we can provide context for the environment in which these programs or policies impact ADAP clients and the broader public health objectives of the Ryan White HIV/AIDS Program. Ultimately, we expect that disseminating these results will support improvements in viral suppression, enhancing both individual health outcomes and public health. International Registered Report Identifier (IRRID): DERR1-10.2196/90008

29 September 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
RPReanna K Panagides
Reanna K Panagides
ERErin Q Rogers
Erin Q Rogers
AKAmy Killelea
Amy Killelea
THTim Horn
Tim Horn
JKJessica Keim-Malpass
Jessica Keim-Malpass
KMKathleen A McManus
Kathleen A McManus
Ryan White HIV/AIDS Part A/B formula awards were historically based on residence at HIV (HIV-1) diagnosis. We modeled the recent switch to current-residence formulas, calculating percent change in awards from 2025 to 2030. Combined awards rise overall, but results vary by region, Medicaid expansion status, and Ending the HIV Epidemic designation.

23 December 2025 in JMIR Preprints
Verified
Preprint
Open access
KMKathleen A McManus
Kathleen A McManus
ERErin Q Rogers
Erin Q Rogers
ASAmber Steen
Amber Steen
AKAmy Killelea
Amy Killelea
THTim Horn
Tim Horn
JKJessica Keim-Malpass
Jessica Keim-Malpass
BACKGROUND AIDS Drug Assistance Programs (ADAPs), a key part of the federally funded Ryan White HIV/AIDS Program, provide antiretroviral therapy (ART) to low-income and uninsured or underinsured people with HIV. As long as they meet federal regulations, jurisdictions maintain flexibility in implementing ADAPs, allowing for a range of operational and programmatic options, including eligibility criteria, formulary design for ART (and non-ART) drugs, and the nature and character of insurance support. These programmatic and policy decisions ultimately impact ADAP client outcomes, including engagement in care, differences in the populations benefiting from ADAP, and viral suppression rates. Despite ADAPs achieving an 85% national average viral suppression rate, this falls short of the 90% goal needed to end the HIV epidemic, and no formal evaluation has examined how specific operational or policy factors drive success across states. OBJECTIVE This qualitative study aims to examine how operational, organizational, and contextual factors shape the ability of ADAPs to improve viral suppression rates among people with HIV enrolled in ADAPs, specifically by identifying the mechanisms that facilitate high performance and viral suppression for all people with HIV. Results will inform how viral suppression outcomes could be improved through policy, program, operational, and organizational changes in ADAP design and implementation. METHODS Using a qualitative descriptive approach guided by the Consolidated Framework for Implementation Research, we conducted semistructured interviews with state-level ADAP leaders, operational and programmatic decision-makers, and staff. Interview questions covered 5 domains: leadership and staffing; operations, integration, and collaboration; formulary design and treatment; eligibility and enrollment; and innovation and implementation. Qualitative data from the interviews will be analyzed using deductive and inductive approaches along with situational mapping. RESULTS This study was funded in April 2023. In total, 33 individuals from 16 states have participated in this qualitative study, resulting in a participation rate of 31.4% (16/51). States from all 4 US census regions were represented. Interviews were conducted between February 12, 2025, and March 20, 2025. As of March 2026, data analysis is underway. CONCLUSIONS We anticipate that the study will highlight features, organizational practices, and operational norms that contribute to the successes of ADAPs with high rates of viral suppression. Successful completion of this analysis will provide evidence to inform state and federal regulations, program development, resource allocation, and prioritization to advance the goal of helping people achieve viral suppression and interrupt HIV transmission, which is a vital public health objective. Using other data alongside our qualitative findings, we can provide context for the environment in which these programs or policies impact ADAP clients and the broader public health objectives of the Ryan White HIV/AIDS Program. Ultimately, we expect that disseminating these results will support improvements in viral suppression, enhancing both individual health outcomes and public health. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/90008

16 July 2026 in JMIR Preprints
Verified
Preprint
Open access
AKAmy Killelea
Amy Killelea
ERErin Q Rogers
Erin Q Rogers
ASAmber Steen
Amber Steen
THTim Horn
Tim Horn
RPReanna K. Panagides
Reanna K. Panagides
KMKathleen A. McManus
Kathleen A. McManus
BACKGROUND AIDS Drug Assistance Programs (ADAPs) are a critical safety net within the federal Ryan White HIV/AIDS Program. ADAPs are operated by state and territorial health departments and provide HIV medication access and insurance assistance for low-income people with HIV (PWH). However, the most recent qualitative study assessment of ADAPs was over 14 years ago. OBJECTIVE The purpose of this study was to better understand administrative, programmatic, clinical, and financial considerations that enable ADAPs to support adherence to HIV medications and ultimately achieve viral suppression, treating uninterrupted structural access to medications as a proximate determinant of downstream adherence behavior. METHODS We conducted a secondary qualitative analysis of interviews with state health department HIV program leaders and ADAP staff; participation was at the state level, with 16 states and 33 individual participants enrolled using maximum variance sampling. Coding was guided by the Exploration, Preparation, Implementation, and Sustainment (EPIS). RESULTS Our secondary analysis identified three domains of ADAP programmatic and policy decisions that support medication adherence: eligibility policies (income thresholds, recertification requirements, and re-enrollment flexibilities), formulary design (open vs. limited formularies, inclusion of newer long-acting therapies, and non-ART medications), and pharmacy access policies (network breadth, dispensing location, and multi-month dispensing). Across each domain, programs described facilitators that reduced medication interruptions and barriers that created gaps in ART access for low-income PWH. CONCLUSIONS ADAPs play a central role in supporting medication adherence for low-income PWH through concrete programmatic and policy decisions. Flexible eligibility policies, broad formularies, and accessible pharmacy networks each reduce barriers to uninterrupted ART access. These findings are particularly timely: as of early 2026, at least two ADAPs have established waiting lists, and multiple states have reduced financial eligibility thresholds or formulary coverage in response to budget pressures. The policies described in this study as facilitators of adherence are the same policies being curtailed. Given this study’s findings, removal of these programs features would be expected to reduce the medication adherence and viral suppression gains ADAPs have achieved for the low-income PWH they serve.